Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporins, Fluoroquinolone, Glycylcycline, Carbapenem, β-Lactam antibiotics, Sulbactam, Aminoglycoside, Polymyxins, Tetracycline, Sulfonamide), By Route of Administration (Parenteral, Oral) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global Acinetobacter pneumonia therapeutics market size was valued at USD 651.3 million in 2023 and is projected to reach  USD 1.0 billion by 2032, registering a CAGR of 5.8% during the forecast period (2024-2032). The rising prevalence of the acinetobacter pneumonia bacterial infection, which poses a serious hazard to public health, is driving the Acinetobacter Pneumonia Therapeutics Market growth.

Acinetobacter pneumonia therapies are the treatments and treatment options used to control and combat Acinetobacter pneumonia, a serious respiratory infection caused by Acinetobacter baumannii. Given Acinetobacter baumannii's propensity to develop resistance to numerous medicines, treating Acinetobacter pneumonia can be difficult, necessitating a multidisciplinary approach.

As the global prevalence of Acinetobacter infections rises, so does the acinetobacter pneumonia therapeutics market share. Acinetobacter pneumonia is a serious respiratory infection caused by the Acinetobacter baumannii bacteria, known for its high resistance to various treatments. This has created a demand for novel and effective therapeutic options. Antibiotics for Acinetobacter pneumonia include carbapenems, cephalosporins, aminoglycosides, and polymyxins. However, the spread of drug-resistant microorganisms remains a major concern.

Highlights

• Cephalosporins account for the largest share of the market by drug class.
• Parenteral led the market by route of administration.

Market Dynamics

Global Acinetobacter Pneumonia Therapeutics Market Drivers

Increasing Incidence of Multi-Drug Resistance Infection

The increased occurrence of multidrug-resistant strains of Acinetobacter baumannii, particularly extensively drug-resistant (XDR) and pan-drug-resistant (PDR) strains, is a significant driver of the Acinetobacter pneumonia treatment industry. Multidrug-resistant diseases are a severe public health concern, necessitating the development of new and effective treatment options for drug-resistant microorganisms. According to MDPI, the prevalence of multidrug-resistant bacterial strains increased dramatically between 2021 and 2023 compared to 2018–2020. In 2021-2023, 641 of 1087 bacterial strains were extensively drug resistant (XDR), whereas 134 were pan-drug resistant. The majority of these bacteria, Acinetobacter baumannii (36.4%) and Klebsiella pneumoniae (39.6%), were discovered in intensive care units (59.8%). 

According to the Centers for Disease Control and Prevention (CDC), Acinetobacter baumannii is one of five bacteria that pose an urgent hazard in the United States. According to the CDC, multidrug-resistant strains cause around 8% of healthcare-associated Acinetobacter infections, posing a significant risk to patient safety and healthcare systems. This is because it can develop resistance to several of the medicines that are regularly used to treat it. Approximately 50% of *A. baumannii* isolates are resistant to multiple medications.

Moreover, outbreak investigations and epidemiological studies add to the body of information supporting the impact of multidrug-resistant Acinetobacter infections on patient outcomes and healthcare systems. These studies frequently uncover common risk factors, transmission channels, and infection control issues related to multidrug-resistant Acinetobacter baumannii strains, emphasizing the significance of focused interventions and treatment measures.

Global Acinetobacter Pneumonia Therapeutics Market Restraints

Limited Treatment Options

One of the critical challenges confronting the Acinetobacter pneumonia treatments industry is growing antibiotic resistance in Acinetobacter baumannii strains. Multidrug-resistant and extensively drug-resistant strains of Acinetobacter baumannii are becoming more widespread, decreasing the efficacy of traditional antibiotic treatments. Resistance to various antibiotic classes lowers healthcare providers' treatment options, making it difficult to manage and treat Acinetobacter pneumonia. According to a global report by the World Health Organization (WHO), Acinetobacter baumannii is a critical priority pathogen due to its high level of antibiotic resistance. The paper emphasizes the increasing prevalence of carbapenem-resistant Acinetobacter baumannii strains, which are linked to limited treatment options and poor clinical outcomes.

Additionally, clinical trials assessing the efficacy of medicines in treating Acinetobacter pneumonia have revealed unsatisfactory response rates, particularly in cases with multidrug-resistant bacteria. For example, a prospective cohort study published in Clinical Infectious Diseases looked at the outcomes of patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii and discovered high rates of treatment failure and mortality despite aggressive antibiotic therapy.

Furthermore, the scarcity of innovative antibiotics for multidrug-resistant Acinetobacter baumannii strains exacerbates the dilemma of limited treatment options. Pharmaceutical companies encounter scientific, regulatory, and commercial obstacles while developing novel antibiotics, resulting in a scarcity of breakthrough therapies for Acinetobacter pneumonia.

Global Acinetobacter Pneumonia Therapeutics Market Opportunity

Development of Novel Antibiotics and Therapeutic Agents

Pharmaceutical corporations and researchers can invest in developing novel antibiotics for multidrug-resistant strains of Acinetobacter baumannii. Researchers can produce novel compounds active against drug-resistant Acinetobacter strains by utilizing innovative drug discovery strategies such as high-throughput screening and structure-based drug design. Furthermore, various therapeutic methods, such as bacteriophage therapy, antimicrobial peptides, and immunomodulatory drugs, show promise in treating Acinetobacter pneumonia and merit further exploration.

In 2023, researchers created Zosurabalpin, a novel antibiotic that can destroy drug-resistant germs. Zosurabalpin inhibits the passage of giant molecules known as lipopolysaccharides to the outer membranes of Acinetobacter baumannii bacteria, causing them to concentrate within the cell. Zosurabalpin has shown promise in fighting pneumonia and sepsis strains in mice, and it may be able to eliminate one of three bacteria thought to pose the greatest threat to human health due to medication resistance. The first clinical trial findings for the drug are expected in 2024.

Other new antibiotics aimed at multidrug-resistant Acinetobacter baumannii strains are also in development. For example, researchers are looking at how novel beta-lactamase inhibitors, such as avibactam and sulbactam, can be combined with existing antibiotics to improve their action against drug-resistant organisms. Preclinical investigations and early-phase clinical trials have yielded positive findings, demonstrating that combination therapy can overcome antibiotic resistance in Acinetobacter pneumonia.

Thus, continued investment in R&D activities is required to bring novel medicines to market to address the unmet medical requirements related to Acinetobacter pneumonia.

Regional Analysis

The global Acinetobacter pneumonia therapeutics market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global Acinetobacter pneumonia therapeutics market shareholder and is estimated to grow at a CAGR of 5.6% over the forecast period. The North American acinetobacter pneumonia therapeutics market dominated the market, accounting for 40% of the total in 2023, owing to the availability of recently introduced medicines such as Xacduro, FDA approvals, and a well-established healthcare infrastructure. The region has a robust healthcare system, strict regulatory systems, increased public awareness, and considerable research initiatives. Furthermore, its geographic accessibility and patient concentration help to cement its dominant position. These variables all contribute to North America's critical role in developing therapeutic approaches for Acinetobacter pneumonia, cementing its position as a market leader.

Furthermore, the United States acinetobacter pneumonia therapeutics market will likely expand during the forecast period, owing to the high prevalence of acinetobacter-related pneumonia infections, a lack of authorized medicines, and a constrained antibacterial pipeline. The market is expected to rise due to increased multidrug-resistant strains and the desire for more effective therapies. Key pharmaceutical companies, including Pfizer, Merck, and GlaxoSmithKline, actively use product innovation and strategic alliances to address antibiotic resistance issues. The U.S. market is expected to grow significantly by 2030, owing to continuous research, treatment advances, and cooperation between industry, research, and healthcare sectors.

Europe is anticipated to exhibit a CAGR of 5.8% over the forecast period. The European acinetobacter pneumonia treatments market is steadily expanding, driven by increased drug-resistant infections and hospital-acquired pneumonia cases. Ongoing research helps to develop personalized medications and improve patient outcomes. Pneumonia's significant prevalence, particularly among the elderly and immunocompromised people, fuels the demand for effective treatments. Demographic shifts toward an elderly population open up additional market prospects. The UK market is steadily growing as drug-resistant illnesses and hospital-acquired pneumonia incidence rise. The growth of multidrug-resistant bacteria, advances in diagnostics, and the need for better therapies are all significant drivers.

Additionally, rising infections, research into virulence factors and resistance, and the development of new antimicrobials drive the French acinetobacter pneumonia treatments market. This innovation strives to enhance treatment outcomes and create safer alternatives. The market in Germany will likely expand over the forecast period, owing to increased research interest, as evidenced by more PubMed publications. Concentrations are found in North Rhine-Westphalia, Hesse, and Baden-Wuerttemberg. This demonstrates a strong regional emphasis on studying and treating Acinetobacter infections, likely affected by local healthcare facilities and research institutes.

The Asia-Pacific market is growing due to rising prevalence, higher healthcare spending, population growth, medical developments, regulatory backing, and increased awareness. Rising pneumonia cases and a burgeoning medical tourism industry help to drive market expansion. Furthermore, increasing healthcare access and awareness in developing countries creates significant growth prospects, allowing more patients to receive diagnosis and treatment for drug-resistant illnesses such as Acinetobacter pneumonia. 

In addition, the China hiacinetobacter pneumonia therapeutics market is predicted to rise during the forecast period due to increasing infection rates, antibiotic resistance, increasing healthcare spending, and expanding healthcare infrastructure. Anticipated growth originates from continued research and development, focusing on new antibiotics and therapy techniques. Japan's market will likely grow during the forecast period, owing to the incidence of carbapenem-resistant Acinetobacter baumannii (CR-AB) isolates and resistance to several antibiotics. Studies have found carbapenemase genes such as blaOXA-23, blaOXA-72, and blaNDM-1 complicate treatment. The demand for novel therapies to successfully manage CR-AB infections drives market dynamics. Future expansion will depend on studies of geographic distribution and resistance mechanisms, focusing on developing novel treatments that address these problems.

The Latin American acinetobacter pneumonia treatments market is likely to expand during the forecast period, driven by rising markets in developing countries, a renewed emphasis on preventative healthcare, and the impact of lower respiratory infections. These issues underline the critical need for new pneumonia treatments. Brazil exhibits global growth trends driven by causes such as developing drug-resistant strains and an increase in hospital-acquired pneumonia infections.

The Middle East and Africa acinetobacter pneumonia therapeutics market will likely develop slowly during the forecast period, owing to lower infection frequency, more research, molecular diagnostic improvements, and a preference for tailored therapy. Urgent medical requirements require increased R&D activities. Molecular diagnostics enable faster, more precise diagnosis, which improves patient outcomes. Targeted medication therapy is becoming increasingly popular due to its efficacy and low risk of resistance.

Segmental Analysis

The global Acinetobacter pneumonia therapeutics market is segmented based on type and route of administration.

The market is further segmented by type into Cephalosporins, Fluoroquinolone, Glycylcycline, Carbapenem, β-Lactam antibiotics, Sulbactam, Aminoglycoside, Polymyxins, Tetracycline, Sulfonamide.

The cephalosporins sector had the most significant market share at 15%. Cephalosporins are a type of beta-lactam antibiotic that prevents bacterial cell wall formation. They are frequently used as first-line treatments for treating Acinetobacter pneumonia. Cephalosporins, such as cefepime and ceftazidime, have activity against Acinetobacter baumannii and are commonly used in combination therapy for severe infections.

Additionally, the rising antimicrobial resistance of acinetobacter baumannii, a significant cause of pneumonia, has limited therapeutic choices, making cephalosporins an essential alternative for therapy. Cephalosporins remain the first line of treatment when isolates are still susceptible to this class of antibiotics, indicating their efficiency in fighting multidrug-resistant Acinetobacter infections. This medicine class includes Ceftazidime and Cefiderocol, which are used to treat acinetobacter pneumonia. 

The sulbactam sector is expected to grow at the quickest CAGR during the forecast period, owing to its approval for treating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in adults. Sulbactam, a β-lactamase inhibitor, is often used with β-lactam antibiotics like ampicillin to broaden their spectrum of activity against β-lactamase-producing bacteria, such as Acinetobacter baumannii. Sulbactam has intrinsic efficacy against some Gram-negative bacteria and may function synergistically when combined with therapy.

Xacduro is a novel medication of the sulbactam class. Xacduro, a sulbactam-sulbactam combination, addresses the critical need for effective treatments against multidrug-resistant strains of Acinetobacter baumannii-calcoaceticus complex. Furthermore, clinical efficacy and safety data from trials such as ATTACK underscore Xacduro's potential as a beneficial addition to the therapeutic arsenal for Acinetobacter pneumonia, supporting its estimated CAGR over the forecast period.

The market can be further bifurcated by route of administration into parental and oral.

The parenteral route of administration segment dominated in 2023 and is predicted to expand at a considerable CAGR due to the severity and criticality of Acinetobacter infections. Parenteral administration involves injecting antibiotics directly into the circulation, avoiding the gastrointestinal tract. This route of administration is widely used to provide antibiotics to hospitalized patients with severe or life-threatening illnesses, such as Acinetobacter pneumonia. Parenteral antibiotics are often given intravenously (IV) or intramuscularly (IM) and allow rapid and consistent absorption into the bloodstream, ensuring that therapeutic medication levels are reached quickly.

Antibiotics are delivered quickly and directly via the IV route, ensuring rapid absorption and potency, making it the recommended technique for treating severe infections such as acinetobacter pneumonia. To effectively battle Acinetobacter Pneumonia, drugs such as Xacduro (sulbactam injection; sulbactam injection), polymyxins (colistin), carbapenems, and aminoglycosides are delivered intravenously. The IV route's dominance is consistent with the urgency and complexity of treating Acinetobacter pneumonia, stressing the significance of prompt and focused therapy for the best patient outcomes.

The oral method of administration sector had the second-largest revenue share in 2023, owing to the immediate treatment accessibility and extensive availability of oral antibiotics. Antibiotics are administered orally, usually as pills, capsules, or liquid formulations. While oral antibiotics are less common than parenteral administration for severe infections such as Acinetobacter pneumonia, they may be utilized in mild to moderate infection or to transfer patients from parenteral to oral medication after clinical improvement is noted. As the global market expands steadily, the increasing acceptance of oral medicines reflects a broader trend favoring oral pharmaceutical use globally. The oral route is critical in offering effective and accessible treatment choices for acinetobacter pneumonia.

Recent Developments

• April 2024- The European Commission approved Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options.
• January 2024- Merck acquired Harpoon Therapeutics, further diversifying its oncology pipeline.
• February 2024- GSK completed its acquisition of Aiolos Bio.
• April 2024- Johnson & Johnson (NYSE: JNJ) revealed that the United States Food and Drug Administration (FDA) approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are resistant to lenalidomide. With this approval, CARVYKTI® becomes the first and only BCMA-targeted medication licensed for the treatment of multiple myeloma patients as early as the first relapse.